Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Türkiye: 48-Month Data, BOSPHORUS-DME Study Group Report No. 1 - PubMed
3 days ago
- #anti-VEGF therapy
- #diabetic macular edema
- #real-world study
- Study evaluates 48-month outcomes of intravitreal anti-VEGF therapy for diabetic macular edema (DME) in Türkiye.
- Retrospective, multicenter study involving 2,424 eyes of 1,696 patients across eight tertiary hospitals.
- Mean baseline best-corrected visual acuity (BCVA) improved from 0.34 to 0.49, and central macular thickness (CMT) decreased from 400 μm to 324 μm at 48 months.
- Average cumulative injections were 6.5, 9.6, 12.2, and 15.7 at years 1, 2, 3, and 4, respectively.
- 43.5% of eyes switched anti-VEGF therapy between months 3 and 6, mostly due to mandatory transition to on-label agents.
- Findings highlight the importance of early intensive therapy and sustained treatment adherence for DME management.